图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
医药载体系统评论综述
影响因子: 2.9 5年影响因子: 3.72 SJR: 0.573 SNIP: 0.551 CiteScore™: 2.43

ISSN 打印: 0743-4863
ISSN 在线: 2162-660X

医药载体系统评论综述

DOI: 10.1615/CritRevTherDrugCarrierSyst.v12.i2-3.20
pages 151-231

Delivery of Biotherapeutics by Inhalation Aerosol

Ralph W. Niven
Amgen, Inc., Room 8-1-C, 1840 DeHavilland Dr., Thousand Oaks, CA 91320-1789

ABSTRACT

The role of inhalation therapy is adapting to changes brought on by advances in several related disciplines. These range from device technology to the molecular and cell biology of the lungs. Acceptable bioavailability and efficacy have been achieved via the oral route for most traditional pharmaceuticals. Unfortunately, injection is the normal mode of delivery with biotherapeutic agents and alternative delivery approaches are needed. Many preclinical and clinical studies with inhaled proteins, peptides, and DNA have been completed and demonstrate that efficacy can be achieved within the lungs and systemically. Despite the promising results, the development of inhaled biotherapeutics is beset with unique problems that require an integrated and rational approach to development. Aqueous protein formulations are often not stable to aerosolization, while stability of powder formulations can be difficult to evaluate in the solid state. Inhaler efficiency and reproducibility are unacceptable with existing devices and, although improvements in technology have brightened the outlook, new devices are not yet available and remain untried with most biotherapeutics. Once delivered to the lungs, these molecules are also subjected to a variety of efficient clearance mechanisms that can significantly reduce the probability of them being effective. Despite these problems, the number of potential drugs being tested via inhalation continues to increase, suggesting some promise of future success. This review discusses the above issues and highlights a variety of biotherapeutics that have been administered as inhalation aerosols.


Articles with similar content:

Current Nanotechnological Strategies for Effective Delivery of Bioactive Drug Molecules in the Treatment of Tuberculosis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 1
Mandeep Kaur, Goutam Rath, Tarun Garg, Amit Kumar Goyal
Oral Colon-Specific Drug Delivery of Protein and Peptide Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 1
Ruchita V. Kumar, Sanjay Singh, Vivek Ranjan Sinha, J. R. Bhinge, Asmita Singh, Rachana Kumria
Pulmonary Drug Delivery Systems: Recent Developments and Prospects
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.19, 2002, issue 4-5
Th. F. Vandamme, N. Butz, H. M. Courrier
Perspectives of Lipid-Based Drug Carrier Systems for Transdermal Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 4
Shikha Srivastava, Madhulika Pradhan, Shailendra Saraf, Deependra Singh, Swarnlata Saraf, Manju Rawat Singh
Enhancement of Transdermal Drug Delivery: Chemical and Physical Approaches
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.17, 2000, issue 6
Bozena Michniak, Ayman F. El-Kattan, Charles S. Asbill